Prosight Management LP Has $3.65 Million Stake in Haemonetics Co. (NYSE:HAE)

Prosight Management LP decreased its position in Haemonetics Co. (NYSE:HAE) by 28.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 46,700 shares of the medical instruments supplier’s stock after selling 18,300 shares during the period. Haemonetics makes up approximately 1.0% of Prosight Management LP’s holdings, making the stock its 23rd biggest position. Prosight Management LP’s holdings in Haemonetics were worth $3,646,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Nomura Holdings Inc. acquired a new position in shares of Haemonetics during the fourth quarter valued at about $519,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Haemonetics by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,570 shares of the medical instruments supplier’s stock valued at $2,231,000 after purchasing an additional 1,084 shares during the period. LMR Partners LLP acquired a new position in shares of Haemonetics during the fourth quarter valued at about $2,059,000. London Co. of Virginia raised its holdings in shares of Haemonetics by 2.2% during the fourth quarter. London Co. of Virginia now owns 281,738 shares of the medical instruments supplier’s stock valued at $21,998,000 after purchasing an additional 6,111 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Haemonetics by 29.9% during the fourth quarter. Janus Henderson Group PLC now owns 60,436 shares of the medical instruments supplier’s stock valued at $4,720,000 after purchasing an additional 13,920 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Down 1.2%

Shares of HAE stock opened at $68.30 on Thursday. Haemonetics Co. has a 52-week low of $55.30 and a 52-week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company has a 50-day simple moving average of $62.84 and a two-hundred day simple moving average of $71.28. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of 26.89, a PEG ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the firm posted $0.90 EPS. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. Research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HAE shares. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC decreased their target price on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Raymond James reissued a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.